092730 — NeoPharm Co Income Statement

0.000.00%

Last trade - 00:00

Consumer DefensivesAdventurousSmall CapSuper Stock

Annual income statement for NeoPharm Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	ARS	Annual Audited Accounts	ARS
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	87,931	85,033	97,105	119,014	132,184
Cost of Revenue
Gross Profit	62,386	58,380	65,385	74,027	86,398
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	65,511	63,601	71,811	94,364	103,410
Operating Profit	22,420	21,433	25,294	24,650	28,774
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	23,836	23,323	29,373	30,209	32,261
Provision for Income Taxes
Net Income After Taxes	17,713	17,027	23,213	23,065	27,823
Minority Interest
Net Income Before Extraordinary Items
Net Income	17,713	17,027	23,213	23,065	27,823
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	17,713	17,027	23,213	23,065	27,823
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	1,133	1,088	1,484	1,471	1,776
Dividends per Share